Profiling of the expression of three studied molecules in this study elucidates to some extent some key clinical aspects of liposarcomas: lack of E-cadherin expression verifies the mesenchymal origin and weak beta-catenin and TOP2α expression provide molecular reasoning of the limited aggressiveness and marginal chemosensitivity of these tumours. Here, CDH1 is linked to liposarcoma.